重组人促卵泡激素研究进展

Advances of recombinant human follicle-stimulating hormone

重组人促卵泡激素(rhFSH)是目前人类辅助生殖技术中常用的药物。由于糖基化作用的原因,原核表达系统难以生产出rhFSH。迄今为止,全球仅有两家公司的rhFSH药物上市。rhFSH高表达细胞株的构建、蛋白产量的提高以及糖基化的均一性是目前需要重点解决的问题。本文综述了rhFSH及其突变体的研发现状和未来的发展趋势,为后续的重组卵泡刺激素研究奠定基础。

Recombinant human follicle-stimulating hormone, rhFSH, is now commonly used in human assistant reproductive technology. However, rhFSH is difficult to be produced by prokaryotic expression system due to its glycosylation, so there are now only two brands of rhFSH in clinics. In the future, it is necessary to develop high expression cell lines to increase rhFSH yield in the process. And the homogeneity of glycosylation of rhFSH will be primarily considered in the production. This review summarizes the advances of the development of rhFSH and its mutants, and lays the foundation for the further research of rhFSH.